| Schedule of Financial Information Including Significant Segment Expenses by Program |
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the three and nine months ended December 31, 2025 and 2024: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended December 31, | | Nine Months Ended December 31, | | 2025 | | 2024 | | 2025 | | 2024 | | Operating expenses: | (Amounts in thousands) | | Direct research and development expenses by program: | | | | | | | | | RP1 program costs by study: | | | | | | | | | IGNYTE | 2,059 | | | 3,226 | | | 8,073 | | | 10,831 | | | ARTACUS | 1,663 | | | 1,787 | | | 4,898 | | | 5,211 | | | CERPASS | 1,012 | | | 1,611 | | | 3,653 | | | 5,573 | | | IGNYTE-3 | 4,219 | | | 2,375 | | | 15,554 | | | 4,909 | | | Other RP1 study costs | 5,200 | | | 1,590 | | | 15,162 | | | 7,075 | | | RP2 | 7,729 | | | 4,409 | | | 16,857 | | | 8,322 | | | RP3 | 826 | | | 1,434 | | | 2,262 | | | 3,856 | | | Unallocated research and development expenses¹: | 30,432 | | | 31,572 | | | 102,401 | | | 89,695 | | | Selling, general and administrative | 18,728 | | | 18,015 | | | 77,721 | | | 46,827 | | | Total operating expenses | 71,868 | | | 66,019 | | | 246,581 | | | 182,299 | | | Loss from operations | (71,868) | | | (66,019) | | | (246,581) | | | (182,299) | | | Other income (expense), net | 627 | | | $ | 254 | | | $ | 5,547 | | | $ | 9,707 | | | Loss before income taxes | $ | (71,241) | | | $ | (65,765) | | | $ | (241,034) | | | $ | (172,592) | | Income tax (benefit) provision | (311) | | | 575 | | | (311) | | | 575 | | | Net loss | (70,930) | | | (66,340) | | | (240,723) | | | (173,167) | | 1Includes personnel-related costs and other costs |